STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

GS Group and Goldman Sachs & Co. LLC Jointly Report 308-Share Stake in TSVT

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

2seventy bio, Inc. Schedule 13G/A shows The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly report beneficial ownership of 308 shares of the issuer's common stock. The filers state no sole voting or dispositive power and report shared voting power of 133 shares and shared dispositive power of 308 shares. The reported amount represents 0.0% of the class and is described as ownership of 5% or less. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing control. The filing includes a joint filing agreement and identifies GS Group as a parent holding company with Goldman Sachs as a subsidiary broker-dealer and investment adviser.

Positive

  • Joint filing agreement included, clarifying reporting responsibilities between GS Group and Goldman Sachs & Co. LLC
  • Ownership is 5% or less, reported as 308 shares (0.0% of class), indicating a de minimis stake
  • Filers certify holdings are in the ordinary course of business and not intended to influence control

Negative

  • None.

Insights

TL;DR: Reported holdings are de minimis—308 shares (0.0%), indicating no material economic or control stake.

The Schedule 13G/A discloses a small, jointly reported position of 308 shares in 2seventy bio. With 0 sole voting/dispositive power and only 133 shared votes, this holding is immaterial to ownership concentration and unlikely to affect capitalization or governance. The filing's certification that the shares are held in the ordinary course and the inclusion of a joint filing agreement confirm routine custody/trading or advisory activity rather than an activist intent. Impact on investors is neutral.

TL;DR: Legal formality of joint Schedule 13G/A; ownership and voting influence are negligible.

The report identifies GS Group and its subsidiary as joint filers and classifies the positions under standard reporting types. The combination of no sole power, shared voting power of 133, and an overall stake of 308 shares (0.0%) indicates no practical governance influence. The explicit certification that holdings are not intended to change or influence control reduces regulatory and activist signaling. This disclosure is routine and non-impactful for board-level or strategic considerations.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



THE GOLDMAN SACHS GROUP, INC.
Signature:Name: Abhilasha Bareja
Name/Title:Attorney-in-fact
Date:07/17/2025
GOLDMAN SACHS & CO. LLC
Signature:Name: Abhilasha Bareja
Name/Title:Attorney-in-fact
Date:07/17/2025
Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of 2SEVENTY BIO, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ Abhilasha Bareja ---------------------------------------- Name: Abhilasha Bareja Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Abhilasha Bareja ---------------------------------------- Name: Abhilasha Bareja Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

How many shares does Goldman Sachs report beneficially owning in TSVT?

The filers report 308 shares beneficially owned.

What voting and dispositive powers are reported for Goldman Sachs in TSVT?

The filing shows 0 sole voting power, 133 shared voting power, 0 sole dispositive power, and 308 shared dispositive power.

What percentage of 2seventy bio (TSVT) does the reported position represent?

The reported position represents 0.0% of the class, and is described as ownership of 5% or less.

Did the filers indicate an intent to influence control of TSVT?

No. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

Who are the reporting persons on this Schedule 13G/A for TSVT?

The reporting persons are The Goldman Sachs Group, Inc. (parent holding company) and Goldman Sachs & Co. LLC (subsidiary broker-dealer and investment adviser).
2Seventy Bio

NASDAQ:TSVT

TSVT Rankings

TSVT Latest News

TSVT Latest SEC Filings

TSVT Stock Data

266.14M
49.56M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
Link
US
CAMBRIDGE